Monitoring vaccine safety during an influenza pandemic
- PMID: 17132333
- PMCID: PMC2259166
Monitoring vaccine safety during an influenza pandemic
Abstract
In the event that a vaccine is available during an influenza pandemic, vaccine safety monitoring will occur as part of comprehensive public health surveillance of the vaccination campaign. Though inactivated influenza vaccines have been widely used in the United States and much is known about their safety profile, attention will need to be paid to both common self-limited adverse reactions and rarer, more serious events that may or may not be causally related to vaccination. The primary surveillance systems used to generate and test hypotheses about vaccine safety concerns are the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Datalink (VSD), respectively. Examples of recent use of these systems to investigate influenza vaccine safety and enhancements planned for use during a pandemic are presented. Ethical issues that will need to be addressed as part of an overall vaccine safety response include risk communication and injury compensation. Advance planning and the use of available technologic solutions are needed to respond to the scientific and logistic challenges involved in safely implementing mass vaccination during a pandemic.
Similar articles
-
Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.MMWR Morb Mortal Wkly Rep. 2009 Dec 11;58(48):1351-6. MMWR Morb Mortal Wkly Rep. 2009. PMID: 20010511
-
Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.Vaccine. 2009 Mar 26;27(15):2114-20. doi: 10.1016/j.vaccine.2009.01.125. Epub 2009 Feb 6. Vaccine. 2009. PMID: 19356614
-
Potential population-based electronic data sources for rapid pandemic influenza vaccine adverse event detection: a survey of health plans.Pharmacoepidemiol Drug Saf. 2008 Dec;17(12):1137-41. doi: 10.1002/pds.1642. Pharmacoepidemiol Drug Saf. 2008. PMID: 18763248
-
Public health strategies for distribution of influenza vaccine during an influenza pandemic.Yale J Biol Med. 2005 Oct;78(5):277-86. Yale J Biol Med. 2005. PMID: 17132334 Free PMC article. Review.
-
Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program.Pediatrics. 2011 May;127 Suppl 1:S78-86. doi: 10.1542/peds.2010-1722L. Epub 2011 Apr 18. Pediatrics. 2011. PMID: 21502251 Review.
Cited by 4 articles
-
Investigating safety profiles of human papillomavirus vaccine across group differences using VAERS data and MedDRA.PeerJ. 2019 Aug 20;7:e7490. doi: 10.7717/peerj.7490. eCollection 2019. PeerJ. 2019. PMID: 31497391 Free PMC article.
-
Role of Pharmacovigilance in India: An overview.Online J Public Health Inform. 2015 Jul 1;7(2):e223. doi: 10.5210/ojphi.v7i2.5595. eCollection 2015. Online J Public Health Inform. 2015. PMID: 26392851 Free PMC article.
-
Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccine.PLoS One. 2012;7(7):e38563. doi: 10.1371/journal.pone.0038563. Epub 2012 Jul 3. PLoS One. 2012. PMID: 22802929 Free PMC article.
-
Hospital discharge data for Guillain-Barré syndrome and influenza A (H1N1) vaccine adverse events.Emerg Infect Dis. 2010 Sep;16(9):1500-1. doi: 10.3201/eid1609.091837. Emerg Infect Dis. 2010. PMID: 20735949 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical